Magnolol Protects against MPTP/MPP+-Induced Toxicity via Inhibition of Oxidative Stress in In Vivo and In Vitro Models of Parkinson's Disease by Muroyama, Akiko et al.
Hindawi Publishing Corporation
Parkinson’s Disease
Volume 2012, Article ID 985157, 9 pages
doi:10.1155/2012/985157
Research Article
Magnolol Protects against MPTP/MPP+-InducedToxicity via
Inhibitionof Oxidative Stress in InVivo andInVitro Models of
Parkinson’s Disease
AkikoMuroyama,1 AyaFujita,1 Cheng Lv,1 Shota Kobayashi,1
Yoshiyasu Fukuyama,2 and YasuhideMitsumoto1
1Laboratory of Alternative Medicine and Experimental Therapeutics, Department of Clinical Pharmacy,
Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Ishikawa 920-1181, Japan
2Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima 770-8514, Japan
Correspondence should be addressed to Yasuhide Mitsumoto, y-mitsumoto@hokuriku-u.ac.jp
Received 5 January 2012; Accepted 20 February 2012
Academic Editor: Russell H. Swerdlow
Copyright © 2012 Akiko Muroyama et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The aim of this study is to investigate the role of magnolol in preventing 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP-) induced neurodegeneration in mice and 1-methyl-4-phenylpyridinium ion-(MPP+-) induced cytotoxicity to human
neuroblastoma SH-SY5Y cells and to examine the possible mechanisms. Magnolol (30mg/kg) was orally administered to
C57BL/6N mice once a day for 4 or 5 days either before or after MPTP treatment. Western blot analysis revealed that MPTP
injections substantially decreased protein levels of dopamine transporter (DAT) and tyrosine hydroxylase (TH) and increased glial
ﬁbrillary acidic protein (GFAP) levels in the striatum. Both treatments with magnolol signiﬁcantly attenuated MPTP-induced
decrease in DAT and TH protein levels in the striatum. However, these treatments did not aﬀect MPTP-induced increase in GFAP
levels. Moreover, oral administration of magnolol almost completely prevented MPTP-induced lipid peroxidation in the striatum.
In human neuroblastoma SH-SY5Y cells, magnolol signiﬁcantly attenuated MPP+-induced cytotoxicity and the production of
reactive oxygen species. These results suggest that magnolol has protective eﬀects via an antioxidative mechanism in both in vivo
and in vitro models of Parkinson’s disease.
1.Introduction
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder characterized by the selective loss of nigral do-
paminergic neurons resulting in reduced striatal dopamine
and the cardinal clinical features such as bradykinesia,
resting tremor, rigidity, and postural instability [1]. Current-
ly, pharmacotherapy and surgical approaches for the treat-
ments of PD can only improve the neurological symptoms
[2]. Furthermore, long-term treatment with the dopamine
precursor levodopa often leads to the development of debili-
tating dyskinesias [2]. Therefore, to search neuroprotective
therapies using pharmacological and nonpharmacological
approaches could be important to delay the progression of
pathogenesis in PD. The cause of PD remains unknown,
but a valuable clue has been suggested by discovery of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; [3]).
MPTP selectively damages the dopaminergic pathways in a
patternsimilartothatseeninPDandinducesaparkinsonian
syndrome in humans, monkeys, and mice [1, 4, 5]. The dis-
coverythatMPTPactsthroughinhibitionofcomplexIofthe
electron transport chain stimulated study of mitochondrial
function in the brains from patients with PD [6, 7]. Mizuno
et al. [8] proposed that energy crisis is the most important
mechanism of nigral cell death in PD. In addition, oxidative
stress has also been implicated as an important contributor
to nigral cell death in PD [9, 10], but it is a secondary phe-
nomenon on respiratory failure, because respiratory failure2 Parkinson’s Disease
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Figure 1: Structures of magnolol and honokiol.
will increase oxygen-free radical and consume glutathione
[11, 12]. Oxidative stress and mitochondrial failure produce
a vicious cycle in nigral neurons.
Magnolol and honokiol are the main constituents of the
stem bark of Magnolia obovata Thunb and Magnolia oﬃci-
nalisRhed[13](Figure 1).Theyhavebeenusedastraditional
medicines in China and Japan and have a wide spectrum of
pharmacological activity [14]. In the central nervous system,
these compounds exhibit anxiolytic and antidepressant-like
eﬀects when taken orally [15, 16]. Moreover, magnolol and
honokiol have neuroprotective eﬀects on the central nervous
system using both in vivo and in vitro models [17–21].
Honokiol reduces infarct brain areas after cerebral ischaemia
of mice associated with suppression of reactive oxygen spe-
cies (ROS) production and preservation of mitochondrial
functions through its antioxidative properties [19]. In cul-
turedratcorticalneurons,honokiolandmagnololshowneu-
rotrophic and neuroprotective eﬀects associated with activa-
tion of the intracellular signal transduction cascade [22, 23].
Furthermore, magnolol and honokiol prevent age-related
learning and memory impairment by preserving cholinergic
neurons in the forebrain in senescence-accelerated prone
mice (SAMP; [20]). Recently, it has been reported that mag-
nolol prevents the loss of dopaminergic neurons in 6-hy-
droxydopamine- (6-OHDA-) treated PD mouse model [21].
Inthepresentstudy,wedemonstratedthatmagnololpre-
vents MPTP-induced neurodegeneration in the mouse mod-
el of PD and 1-methyl-4-phenylpyridinium ion-(MPP+-) in-
duced cytotoxicity to human neuroblastoma SH-SY5Y cells.
Furthermore,wefoundthatitsneuroprotectiveeﬀectagainst
these toxins could be associated with the attenuating the
oxidative stress in both in vivo and in vitro studies.
2.MaterialsandMethods
2.1. Animals. Male C57BL/6N mice (9–12 weeks, Charles
River Japan, Atsugi, Japan) were used. They were housed at
an ambient temperature of 23 ± 2◦C under a 12h light/12h
dark cycle (lights on, 7:00 AM) with free access to food and
water. All procedures were performed in accordance with the
Guidelines for Animal Care and Use in Hokuriku University.
2.2. Drug Preparation and Treatment. MPTP hydrochloride
(Sigma-Aldrich, MO, USA) was dissolved in saline and ad-
ministered intraperitoneally (i.p.). Magnolol was isolated
from methanol extract of the M. oﬃcinalis Rhed. The purity
wasdeterminedbyhighperformanceliquidchromatography
(single peak) and by nuclear magnetic resonance spectra
[24]. It was dispersed in a saline suspension containing 5%
Gum arabic and orally administered using an oral-zonde
needle. In the pre-MPTP treatment with magnolol, the mice
(3-4 per group) received magnolol (30mg/kg) for 5 consec-
utive days and were injected MPTP (20mg/kg every 2h, four
times) [25] at the day after the last magnolol administration.
Control mice were administered those vehicles. The mice
were killed at 3 days after the MPTP treatment. In the post-
MPTP treatment with magnolol, the mice (3-4 per group)
received a single injection of MPTP (40mg/kg), and then
magnolol (30mg/kg/day) was administered at the day just
after MPTP treatment and given daily for 4 consecutive days.
The mice were killed at 1h after the last magnolol adminis-
tration.
2.3. Western Blot Analysis. Western blot analysis was per-
formed as described previously [25]. The striatal tissues were
homogenized in ice-cold homogenization buﬀer (0.32M
sucrose containing 4μg/mL pepstatin, 5μg/mL aprotinin,
20μg/mL trypsin inhibitor, 4μg/mL leupeptin, 0.2mM
PMSF, 2mM EDTA, 2mM EGTA, and 20mM Hepes, at pH
7.2) using a microtube homogenizer. Protein concentrations
were determined using BCA Protein Assay Kit (Pierce, IL,
USA).ThehomogenatesweresolubilizedwithLaemmlisam-
ple buﬀer and subjected to 10% sodium dodecyl sulphated-
polyacrylamide gel electrophoresis at 20μgp r o t e i np e r
lane, and then transferred onto polyvinylidene diﬂuoride
(PVDF) membranes (Millipore, MA, USA). Blots were incu-
bated with rat monoclonal antibody against the dopamine
transporter (DAT, MAB369, Chemicon, CA, U.S.A.), rabbit
polyclonal antibody against the tyrosine hydroxylase (TH,
AB152, Chemicon) and mouse monoclonal antibody against
the glial ﬁbrillary acidic protein (GFAP, Sigma-Aldrich,
MO, U.S.A.). The mouse monoclonal antibody against the
actin (MAB1501, Chemicon) was used as a loading control.
The membranes were incubated with alkaline phosphatase-
conjugatedsecondaryantibody,andthendevelopedinaccor-
dance with the manufacturer’s instructions. The densities of
immunoreactive bands were analyzed by image analysis soft-
ware (Image J 1.36, NIH). Densitometric analysis was per-
formedtoquantifyrelativeproteinlevelagainstactinprotein.
2.4. Measurement of Lipid Peroxidation. Lipid peroxidation
was assessedby determining the concentrations of thiobarbi-
turicacidreactivesubstances(TBARS).TheTBARSdetermi-
nation was performed as described previously with a minor
modiﬁcation [26]. The striatal tissue was homogenized in
homogenization buﬀer without sucrose, and treated with
SDS (8%, w/v), acetic acid (20%), and thiobarbituric acid
(0.8%). The resulting mixture was incubated at 95◦Cf o r
60min. After cooling at room temperature, 2.5mL of n-
butanol and pyridine (15:1) was added, and the mixture
was shaken vigorously. After centrifugation at 1,600×gf o r
10min, the absorbance of the supernatant (organic layer)
was measured at 532nm using a Fluorescence Spectropho-
tometer F-4500 (Hitachi Koki Co., Ltd.).Parkinson’s Disease 3
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Figure 2: Eﬀect of pre-MPTP treatment with magnolol on DAT, TH and GFAP protein levels in the striatum of C57BL/6 mice. Mice were
administered daily with magnolol (30mg/kg) for 5 days, and received 4 injections of 20mg/kg MPTP at 2h intervals at the day after the last
magnolol treatment. The evaluations were performed at 3 days after MPTP treatment. Representative immunoblots of DAT, TH and GFAP
protein in the striatum are shown (a). Actin protein was used as housekeeping protein. Immunoblots of DAT (b), TH (c), and GFAP (d) in
the striatum were quantiﬁed in each group. Densitometric analysis of protein bands were performed using software (Image J 1.36, NIH).
The data were expressed as % of control. Results are means ± SD (n = 6-7) from two independent experiments. Statistical comparisons were
carried out by one-way ANOVA followed by Scheﬀet e s t .∗∗∗P<0.001 versus control, #P<0.05 versus MPTP + vehicle.
2.5. Cell Culture and Drug Preparation. Human neuroblas-
toma SH-SY5Y cells were obtained from Otsuka Pharma-
ceutical Co. Ltd. (Tokushima, Japan). Cultures were main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum,
100U/mL penicillin, 100μg/mL streptomycin at 37◦Cu n d e r
a humidiﬁed atmosphere of 95% air and 5% CO2.
MPP+ iodide (Sigma-Aldrich, MO, USA) was dissolved
in the treatment medium, serum-free DMEM plus 1% N2-
supplement (Invitrogen Corp., CA, USA). A stock solution
ofmagnololwaspreparedindimethylsulfoxide(DMSO;ﬁnal
concentration 0.1%) and dissolved in same medium.
2.6. Alamar Blue Assay. Mitochondrial oxidation-reduction
(REDOX) activity was estimated using Alamar blue dye
(Invitrogen Corp., CA, USA). Alamar blue is a ﬂuorescent
indicator that is intermediate only between ﬁnal reduction of
molecularoxygenandcytochromeoxidase.Cellswereseeded
in 96-well plates at the density of 1.0 × 105 cells/cm2 and
cultured in the growth medium for 48h. The medium was
c h a n g edt os e ru m - f r eeD M E Mp l u s1 %N 2 - s u p p l e m e n tc o n -
taining MPP+ and/or magnolol. At 24h after treatment, cells
were incubated with Locke’s buﬀer (154mM NaCl, 5.6mM
KCl,2.3mMCaCl2,1.0mMMgCl 2,3.6mMNaHCO3,5mM
glucose, 5mM Hepes, at pH 7.2) containing 10% Alamar
blue dye for 2h at 37◦C. Alamar blue ﬂuorescence was meas-
ured using a ﬂuorometric plate reader (Fluoroskan Ascent,
Thermo Fisher Scientiﬁc K.K., Vantaa, Finland) at 544nm
excitation and 590nm emission.
2.7. Measurement of Intracellular ROS Production. Intracel-
lularROSproductionwasmeasuredbyusingaROS-sensitive
ﬂuorescent dye, 2 7 -dichlorodihydroﬂuorescein diacetate
(H2DCF-DA, Invitrogen Corp., CA, USA). SH-SY5Y cells
were seeded in 96-well plates at the density of 1.5 ×
105 cells/cm2 and cultured in the growth medium for 48h.
C e l l sw e r el o a d e dw i t hs e r u m - f r e eD M E Mp l u s1 %N 2 -
supplement containing 10μMH 2DCF-DA for 30min at4 Parkinson’s Disease
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Figure 3: Eﬀect of post-MPTP treatment with magnolol on DAT, TH, and GFAP protein levels in the striatum of C57BL/6 mice. Mice
were received a single injection of 40mg/kg MPTP and administered daily with magnolol (30mg/kg) for 4 days at the day just after MPTP
treatment.Theevaluationswereperformedat1hafterthelasttreatmentwithmagnolol.RepresentativeimmunoblotsofDAT,TH,andGFAP
protein in the striatum are shown (a). Actin protein was used as house keeping protein. Immunoblots of DAT (b), TH (c), and GFAP (d) in
the striatum were quantiﬁed in each group. Densitometric analysis of protein bands was performed using software (Image J 1.36, NIH). The
data were expressed as % of control. Results are means ± SD (n = 3-4) from three independent experiments. Statistical comparisons were
carried out by one-way ANOVA followed by Tukey test. ∗∗∗P<0.001 versus control, #P<0.05 versus MPTP + vehicle.
37◦C, and then MPP+ and/or magnolol were treated for 24h.
The ﬂuorescent intensity of 2 7 -dichloroﬂuorescein (DCF)
was measured using a plate reader at 485nm excitation and
538nm emission.
2.8. Statistical Analysis. The statistical signiﬁcance of the
diﬀerences with absolute values was assessed by one-way
ANOVA followed by Tukey test or Dunnett’s test. The
analyses were performed with the statistical analysis system
StatMate III (ATMS Co., Ltd., Tokyo, Japan). A probability
value of less than 5% was considered statistically signiﬁcant.
3. Results
3.1.Eﬀect of Pre- and Post-MPTP Treatment with Magnolol on
Dopaminergic Neurotoxicity in C57BL/6 Mice. We evaluated
the eﬀect of pre- and post-MPTP treatment with magnolol
on striatal dopaminergic neurons in mice. In the pre-MPTP
treatment with magnolol, mice were administered daily with
magnolol (30mg/kg) for 5 days and received 4 injections
of 20mg/kg MPTP at 2h intervals at the day after the last
treatment with magnolol (Figure 2). Protein levels of DAT,
TH, and GFAP were changed to 17%, 41% and 250% of
control by MPTP treatment, respectively (Figures 2(b), 2(c),
and 2(d)). Pre-MPTP treatment with magnolol signiﬁcantly
attenuated MPTP-induced decrease in DAT and TH protein
levels to 33% and 57% of control, respectively (Figures 2(b)
and 2(c)), whereas the increase in GFAP levels were not
aﬀected (Figure 2(d)). In the post-MPTP treatment with
magnolol, mice were received a single injection of 40mg/kg
MPTP and administered daily with magnolol (30mg/kg)
for 4 days at the day just after MPTP treatment (Figure 3).
Protein levels of DAT, TH, and GFAP were changed to
33%, 47%, and 220% of control by MPTP injection, respec-
tively (Figures 3(b), 3(c),a n d3(d)). Post-MPTP treatment
with magnolol signiﬁcantly attenuated the MPTP-induced
decrease in DAT and TH protein levels to 48% and 64%
of control, respectively (Figures 3(b) and 3(c)), whereas the
increase in GFAP levels was not aﬀected (Figure 3(d)). Mag-
nolol alone did not signiﬁcantly aﬀect these protein levels.
3.2. Eﬀect of Magnolol on Lipid Peroxidation in MPTP-Treated
Mice. To determine the mechanism whereby magnolol pre-
vent loss of dopaminergic neurons, we examined the eﬀectofParkinson’s Disease 5
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Figure 4: Eﬀect of magnolol on lipid peroxidation levels in the
striatum of MPTP-treated C57BL/6 mice. Mice were received a
singleinjectionof30mg/kgMPTPandadministeredwithmagnolol
(30mg/kg) at the day just after MPTP treatment. At 6h after
MPTP treatment, the lipid peroxidation products were measured as
TBARS in the striatum. These are representative results from three
independent experiments. The data were expressed as % of control.
Results are means ± SD (n = 3). Statistical comparisons were
carried out by one-way ANOVA followed by Tukey test. ∗P<0.05
versus control, #P<0.05 versus MPTP + vehicle.
magnolol on MPTP-induced lipid peroxidation in the stri-
atum (Figure 4). The level of TBARS is an index of lipid
peroxidation and indicated as markers of oxidative stress
status in the MPTP mouse model [26]. Mice were received
a single injection of 30mg/kg MPTP and administered with
magnolol (30mg/kg) at the day just after MPTP treatment.
TBARS level increased to 168% of control level in the
striatum at 6h after MPTP injection. Oral administration
of magnolol almost completely inhibited the MPTP-induced
increase in TBARS levels.
3.3. Eﬀe c to fM a g n o l o lo nM P P +-Induced Cytotoxicity in
Human Neuroblastoma SH-SY5Y Cells. To investigate the
action of MPP+,at o x i cm e t a b o l i t eo fM P T P ,o nm i t o c h o n -
drial REDOX activity, human neuroblastoma SH-SY5Y cells
were treated with various concentration of MPP+ (0.5–
5.0mM) for 24h. Mitochondrial REDOX activity, as an indi-
cator of cytotoxicity, was assessed by the Alamar blue ﬂuo-
rescence. MPP+-induced cytotoxicity showed the concen-
tration-dependent manner (Figure 5(a)). But we conﬁrmed
that most of the cells detached from the plate with the
concentration of 5.0mM (data not shown). Therefore, the
concentrationof2.5mMMPP+ waschosenfortheinduction
of decrease in mitochondrial REDOX activity with the
incubation time of 24h. To examine the eﬀect of magnolol
on MPP+-induced cytotoxicity, cells were treated to 2.5mM
MPP+ in thepresenceorabsenceofmagnolol(1or3μM)for
24h (Figure 5(b)). Mitochondrial REDOX activity decreased
to 67% of control by 2.5mM MPP+ treatment. Treatment
with 1 or 3μM magnolol signiﬁcantly attenuated MPP+-in-
duced decrease to 85% or 83% of control, respectively. Mag-
nolol alone did not aﬀect mitochondrial REDOX activity.
3.4. Eﬀe c to fM a g n o l o lo nM P P +-Induced ROS Production.
T h ep r o t e c t i v ee ﬀect of magnolol on MPP+-induced cyto-
toxicity may be the result of attenuating the ROS production.
To examine this possibility, cells were treated with magnolol
and MPP+ for 24h, and ROS production was measured
by using the ﬂuorescent dye H2DCF-DA (Figure 6). MPP+
treatment led to a 2 fold increase in DCF ﬂuorescence
compared with vehicle treatment. Treatment with magnolol
(1or3μM)almostcompletelyinhibitedMPP+-inducedROS
production. Magnolol alone did not aﬀect ROS production.
4. Discussion
In the present study, in vivo and in vitro models of PD were
used to examine the neuroprotective properties of magnolol.
We ﬁrst evaluated the oral administration of magnolol eﬀec-
tively protects striatal dopaminergic neurons in the MPTP-
treated mouse model of PD. Magnolol is rapidly absorbed
from the gastrointestinal tract after oral administration and
peaks in the blood within 15min of administration [27].
Moreover, it is rapidly accumulated in the various regions
of brain after intravenous administration [28]. Therefore,
we presume that oral administered magnolol is absorbed
from the gastrointestinal tract, cross the blood-brain barrier,
accumulatedandactonthebrainincludingstriatumofmice.
Our results demonstrated that both pre- and post-MPTP
treatment with magnolol signiﬁcantly prevented MPTP-
induced decrease in DAT and TH protein levels in the
striatum (Figures 2(b) and 2(c), 3(b),a n d3(c)). However,
both treatments with magnolol did not attenuate MPTP-
induced increase in GFAP levels (Figures 2(d) and 3(d)). The
reason for this discrepancy is still unknown. GFAP is well
known to be a marker for reactive astrocytes in the response
to central nervous system injury [29]. Magnolol may prevent
the dopaminergic neuron associated with the activation of
astrocytes in MPTP-induced neurotoxicity, however it did
not aﬀect GFAP levels in normal condition. The several
studies have shown that astrocytes can confer neuronal
protection by synthesizing and releasing the free-radical
scavenger glutathione [30, 31]. In addition, the activated
astrocytes may stimulate microglial cells, which induce
dopaminergic sprouting via the synthesis of neurotrophic
factors [32]. Moreover, we evaluated the eﬀect of magnolol
against MPTP-induced oxidative stress in an in vivo model.
At 6h after MPTP treatment, dopaminergic neurodegenera-
tionwasnotidentiﬁedinthestriatum,becauseDAT,TH,and
GFAP protein levels as determined by western blot analysis
were not changed in the striatum as compared with that
of control mice (data not shown). We found that MPTP
treatment induces the increase in lipid peroxidation product
TBARS levels before the loss of dopaminergic neurons, and
magnolol inhibit the TBARS production (Figure 4). It is
well known that magnolol has antioxidant and free-radical
scavenging activities [33–35]. These ﬁndings indicate that
oral administration of magnolol prevents MPTP-induced
dopaminergic neurodegeneration, and its protective eﬀect
could be, at least in part, associated with the attenuation
of MPTP-induced oxidative stress. It is unlikely that the6 Parkinson’s Disease
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Figure 6: Eﬀect of magnolol on ROS production in MPP+-treated
human neuroblastoma SH-SY5Y cells. Cells were incubated with
H2DCF-DA for 30min at 37◦C. And then, 2.5mM MPP+ in the
presence or absence of magnolol (1 or 3 μM) were exposed for
24h. ROS production was assessed by DCF ﬂuorescence. These are
representative results from two independent experiments. Results
are means ± SD (n = 3). Statistical comparisons were carried out
by one-way ANOVA followed by Dunnett’s test. ∗P<0.05 versus
vehicle (DMSO), ##P<0.01 versus MPP+ + vehicle (DMSO).
protective eﬀects of magnolol are mediated through inhibi-
tion of monoamine oxidase-B (MAO-B), because magnolol
is inactive against both types of MAO-A and MAO-B from
rat brain mitochondria [36].
In order to investigate whether magnolol could directly
protectagainstMPP+-inducedcytotoxicity,weusedaninvit-
ro systemhumanneuroblastomaSH-SY5Ycells.Alamarblue
is a ﬂuorescent indicator that is intermediate only between
ﬁnalreductionofmolecularoxygenandcytochromeoxidase.
Therefore, the REDOX potential of Alamar blue allows
for the respiratory chain to function to near completion,
which will provide a more accurate and sensitive indication
of mitochondrial function. Mitochondrial REDOX activity
was observed to decline after MPP+ treatment, and treat-
ment with magnolol reduced this decline (Figure 5(b)). In
addition, we conﬁrmed that magnolol improved MPP+-in-
duced morphological changes observed during apoptosis
in the neuroblastoma (data not shown). ROS production
was found to increase after MPP+ treatment, and treatment
with magnolol suppressed signiﬁcantly MPP+-induced ROS
production (Figure 6). These results indicate that magnolol
protects directly the neuroblastoma against the toxic-insult
through the antioxidative activity.
The neurotoxic eﬀects of MPTP are thought to be med-
iated by its metabolite MPP+ which is caused by the oxida-
tion of MPTP by MAO-B in glial cells [37]. MPP+ is tak-
en up by dopaminergic neurons via DAT as it has a high
aﬃnity for this transporter [38]. Several in vitro studies
have suggested that MPP+ is concentrated within mitochon-
dria [39] and inhibits mitochondria complex I in the mito-
chondrial respiratory chain [40]. This damage can lead to
a number of deleterious eﬀects on mitochondrial function,
including the loss of mitochondrial membrane potential and
inhibition of mitochondrial ATP production [41, 42]. In ad-
dition, inhibition of complex I increases the production of
ROS, which impairs the electron transport and ATP pro-
duction [11, 12, 43]. Therefore, the observed MPP+-in-
duceddecreaseinthemitochondrialREDOXactivitymayre-
ﬂect the extent of mitochondrial damage due to increase of
ROSproduction.Wehavefoundthatmagnololwaseﬀective-
lypreservingmitochondrial REDOXactivity,perhapsatleastParkinson’s Disease 7
in part, through anti-oxidative eﬀect. However, the mech-
anism is not fully understood whether magnolol improves
MPP+-induced mitochondrial failure such as decrease in
membrane potential. Further studies are needed to investi-
gate the precise protective mechanism of magnolol against
MPTP/MPP+-induced cytotoxicity.
Recent report has shown that subchronic treatment with
magnolol signiﬁcantly ameliorates apomorphine-induced
contralateral rotation in 6-OHDA-treated mice and prevents
6-OHDA-induced decrease in TH protein levels in the stri-
atum [21]. Because 6-OHDA-induced toxicity is relatively
selective for catecholaminergic neurons, neurotoxin to is
widely used produce PD models [44, 45]. The mechanisms
underlying toxicity of 6-OHDA is involved in the production
of several toxic oxidative species including superoxide ra-
dicals, hydrogen peroxide, and hydroxyl radicals [46, 47].
Therefore, magnolol has exhibited neuroprotective eﬀect in
other PD mouse model via perhaps its antioxidative proper-
ties.
Another mechanism that may explain the protective
eﬀectofmagnololinpreventingMPTP/MPP+-inducedcyto-
toxicity is the regulation of neurotrophic eﬀect. It has been
reported that magnolol and honokiol promote the neurite
outgrowth and enhance the neuronal survival through these
neurotrophic eﬀects in cultured rat cortical neurons [22]. In
6-month-old SAMP8 mice, 14-day treatment with magnolol
(10mg/kg) at 2 months of age prevented an age-related
decrease in the density of cholinergic neurons mediated
the increase of Akt phosphorylation in the forebrain [20].
Akt pathway is well known as a prominent regulator of
neurotrophin-mediated survival responses in neurons [48].
Several lines of evidence indicated that the Akt signaling
pathway responds to oxidative stress, and the promotion of
Akt phosphorylation exerts a neuroprotective eﬀects in the
m o d e lo fP D[ 49, 50].
In conclusion, our results clearly demonstrate that mag-
nolol protects against MPTP/MPP+-induced toxicity in
both in vivo and in vitro models of PD. The protective
mechanism could be partly associated with its anti-oxidative
eﬀect. Magnolol may be a useful therapeutic agent for the
neuroprotective treatment of idiopathic PD.
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